Supportive care

A phase 1/2 study of an adjuvanted varicella-zoster virus subunit candidate vaccine in adult autologous hematopoietic stem-cell transplant recipients. Stadtmauer EA et al. Blood. 2014 Sep 18. pii: blood-2014-04-573048. [Epub ahead of print]. Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of…

General

Harnessing the immune system for cancer therapy. Smith EL et al. Curr Opin Oncol. 2014 Sep 23. [Epub ahead of print]. CCN1: a sticky issue in myeloma. Roodman GD. Blood. 2014 Sep 25;124(13):2006-8. doi: 10.1182/blood-2014-08-592303. Appraising Myc involvement in high risk myeloma. Kastritis E et al. Leuk Lymphoma. 2014 Sep 26:1-5. [Epub ahead of print].…

Complications of myeloma and its treatments

Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients. Engels EA et al. Bone Marrow Transplant. 2014 Sep 29. doi: 10.1038/bmt.2014.213. [Epub ahead of print]. Prevalence of autoimmune hemolytic anemia in multiple myeloma: A prospective study. Kashyap R et al. Asia Pac J Clin Oncol. 2014 Sep 22.…

Current treatments

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. Benboubker L et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Moreau P et al. Br J Haematol. 2014 Sep 19. doi: 10.1111/bjh.13128. [Epub ahead of print]. Bortezomib, thalidomide and…

Related conditions

Diffuse Parenchymal Pulmonary Amyloidosis Showing an Objective Response to Bortezomib-based Chemotherapy. Higo H et al. Intern Med. 2014;53(16):1809-12. Epub 2014 Aug 15. Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. Kourelis TV et al. Am J Hematol. 2014 Aug 11. doi: 10.1002/ajh.23827. [Epub ahead of print]. Immunophenotypic analysis of…

General

Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Hultcrantz M et al. Cancer Med. 2014 Aug 26. doi: 10.1002/cam4.316. [Epub ahead of print]. Bortezomib in multiple myeloma: systematic review and clinical considerations. Kouroukis TC et al. Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Novel Agents In Cns Myeloma Treatment.…

Supportive care

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.Iyer SP et al. Br J Haematol. 2014 Aug 19. doi: 10.1111/bjh.13056. [Epub ahead of print].Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis.Frediani…

Complications of myeloma and its treatments

Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. Kosturakis AK et al. J Clin Oncol. 2014 Aug 25. pii: JCO.2013.54.5418. [Epub ahead of print]. Hepatitis B virus reactivation in multiple myeloma patients receiving bortezomib-containing regimens followed by autologous stem cell transplantation. Li J et al. Leuk…